300146.SHE By health
- Market cap
- CNY 17.5B
- P/E
- 23.6x
- P/B
- 1.51x
- ROE
- 9.8%
- Dividend yield
- 3.45%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300146.SHE undervalued?
Graham number300146.SHE trades 25.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
By health fundamental analysis
No fundamental analysis for By health yet.
By health stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About By health
Byhealth Co., Ltd, together with its subsidiaries, provides dietary supplements in China, Hong Kong, Australia, and internationally. It offers protein powder; collagen; bone health products, including glucosamine, chondroitin, and calcium tablets; probiotics; capsules; and multivitamins under the By-Health, Jianlidu, LifeSpace, and other brand names. The company also engages in scenic area tourism management; real estate; trade and investment; sale of food; trademark managem…
Full company profileBy health financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
By health annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.31B | 3.11B | 4.35B | 5.26B | 6.09B | 7.43B | 7.86B | 9.41B | 6.84B | 6.22B | 7.06B |
| Gross Profit | 1.48B | 2.08B | 2.92B | 3.44B | 3.82B | 4.89B | 5.36B | 6.47B | 4.52B | 4.02B | 4.92B |
| Operating Income | 636M | 878M | 1.10B | -465M | 1.79B | 2.03B | 1.61B | 2.07B | 824M | 888M | 1.30B |
| EBITDA | 638M | 858M | 1.22B | 1.43B | 1.57B | 2.01B | 1.77B | 2.07B | 964M | 1.18B | 1.40B |
| Net Income | 535M | 766M | 1.00B | -356M | 1.52B | 1.75B | 1.39B | 1.75B | 653M | 782M | 1.08B |
| EPS | 0.37 | 0.52 | 0.69 | -0.24 | 0.96 | 1.03 | 0.82 | 1.03 | 0.38 | 0.47 | 0.64 |
| Balance Sheet | |||||||||||
| Total Assets | 5.33B | 6.11B | 9.89B | 8.33B | 9.75B | 13.0B | 13.2B | 15.1B | 14.3B | 14.0B | 13.7B |
| Total Liabilities | 625M | 982M | 2.92B | 2.40B | 2.76B | 2.43B | 2.40B | 2.86B | 3.18B | 2.78B | 2.54B |
| Shareholders' Equity | 4.68B | 5.10B | 5.67B | 5.99B | 6.98B | 10.5B | 10.7B | 12.2B | 11.1B | 11.1B | 11.1B |
| Cash & Short-term Investments | 2.67B | 3.35B | 2.68B | 2.51B | 1.87B | 3.14B | 4.79B | 4.70B | 4.60B | 6.34B | 1.54B |
| Total Debt | 95.9M | 80.7M | 1.05B | 351M | 179M | 41.4M | 3.92M | 161M | 1.54B | 1.03B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 685M | 954M | 1.35B | 1.54B | 1.57B | 1.82B | 1.38B | 2.05B | 686M | 1.38B | - |
| Capital Expenditure | 150M | 154M | 251M | 332M | 322M | 263M | 245M | 1.26B | 306M | 133M | 132M |
| Free Cash Flow | 534M | 800M | 1.10B | 1.20B | 1.24B | 1.56B | 1.13B | 794M | 380M | 1.24B | 266M |
| Ratios | |||||||||||
| ROE | 11.4% | 15.0% | 17.7% | -5.9% | 21.8% | 16.7% | 13.0% | 14.4% | 5.9% | 7.0% | 9.8% |
| ROA | 10.0% | 12.5% | 10.1% | -4.3% | 15.6% | 13.5% | 10.5% | 11.6% | 4.6% | 5.6% | 7.9% |
| Net Profit Margin | 23.2% | 24.6% | 23.0% | -6.8% | 25.0% | 23.6% | 17.6% | 18.6% | 9.5% | 12.6% | 15.3% |
| Debt to Equity | 0.02x | 0.02x | 0.19x | 0.06x | 0.03x | 0.00x | 0.00x | 0.01x | 0.14x | 0.09x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
By health dividends
- Dividend yield
- 3.45%
- Forward dividend
- 0.45 CNY
- Payout ratio
- 77.5%
- Ex-dividend date
- Apr 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 606M | 0.36 | 77.5% |
| 2024 | CNY 1.52B | 0.88 | 232.3% |
| 2023 | CNY 306M | 0.18 | 17.5% |
| 2022 | CNY 1.19B | 0.70 | 85.9% |
| 2021 | CNY 1.11B | 0.65 | 63.1% |
| 2020 | CNY 570M | 0.36 | 37.4% |
| 2019 | CNY 734M | 0.50 | - |
| 2018 | CNY 504M | 0.35 | 50.3% |
| 2017 | CNY 379M | 0.26 | 49.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Apr 1, 2016.
Who owns By health
- Insiders 49.59%
- Institutions 5.61%
- Public & others 44.80%
- Shares outstanding 1.69B
- Free float 916M
By health company profile
- Company name
- By health
- Ticker
- 300146.SHE
- ISIN
- CNE100000Y84
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 15, 2010
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 2,867
- Fiscal year end
- December
- Address
- No. 916, Huangpu Avenue East, Guangzhou, China, 510700
- Phone
- 86 20 2895 7910
- Website
- by-health.com
About By health
Byhealth Co., Ltd, together with its subsidiaries, provides dietary supplements in China, Hong Kong, Australia, and internationally. It offers protein powder; collagen; bone health products, including glucosamine, chondroitin, and calcium tablets; probiotics; capsules; and multivitamins under the By-Health, Jianlidu, LifeSpace, and other brand names. The company also engages in scenic area tourism management; real estate; trade and investment; sale of food; trademark management; and OTC licensing and outsourced processing activities. It sells its products through retail terminals, such as pharmacies, supermarkets, and maternity and baby stores, as well as distributors; and e-commerce platforms comprising Tmall, JD.com, Vipshop, Douyin, and Kuaishou. The company was formerly known as Guangdong By-Health Biotechnology Co., Ltd. and changed its name to Byhealth Co., Ltd in April 2012. Byhealth Co., Ltd was incorporated in 1995 and is based in Guangzhou, China.
By health management
5- Mr. Zhicheng LinCEO & Non-Independent Director · born 1968
- Mr. Bailin HeChief Financial Officer · born 1985
- Ms. Jinyin TangSecretary to the Board of Directors · born 1985
- Mr. Hong ChenDeputy General Manager · born 1966
- Run Shan HeAccounting Supervisor